Karyopharm Therapeutics Inc. buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 03.12.18 mit einem Endkurs von 8,95 € beendet. Die BUY Einschätzung von klostergang zeigte mit einer Rendite von 8,65 % einen positiven Trend. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Karyopharm Therapeutics Inc. | 1,84 % | 1,84 % | -52,23 % | -86,18 % |
iShares Core DAX® | -0,05 % | 4,83 % | 17,06 % | 18,81 % |
iShares Nasdaq 100 | 1,66 % | 2,42 % | 38,70 % | 56,56 % |
iShares Nikkei 225® | 0,66 % | -2,17 % | 13,16 % | 7,77 % |
iShares S&P 500 | 0,96 % | 2,55 % | 30,49 % | 47,35 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion Karyopharm Therapeutics Inc. diskutieren
Karyopharm with an evolving and diverse pipeline
The company’s main focuses can be broken down into 4 areas of therapy:
hematological malignancies, solid tumors, additional oncology programs,
and an “others” category. The company’s lead drug candidate is Selinexor, which is currently in 4 trials for hematological malignancies and 3 trials for solid tumors.
In April of 2017, at the American Association for Cancer Research annual meeting the company reported a 28.6% overall response rate observed in the ongoing Phase 2b SADAL study. Provided that the data is positive, the company will seek a NDA submission in 2018. Lastly, solid tumors is the third leading indication for Selinexor. In March of 2017, the company completed enrollment in the Phase 2 portion of the randomized Phase 2/3 SEAL study evaluating Selinexor versus placebo in patients with advanced liposarcoma after at least one prior therapy. The company will report the top-line data from the Phase 2 portion of this study in mid-2017.
Wall Street seems to have a positive view on KPTI’s prospects with 7 buy ratings, 0 hold ratings, and 0 sell recommendations. The consensus price target currently sits at just over $15.00 a share, which represents an upside of approximately 50%. The latest recommendation comes via Cantor Fitzgerald on May 15th, 2017. The firm reiterated their overweight rating and kept their price target at $18. Cantor stated that they think the presentation at the European Hematology Association could bring about support for KPTI’s DLBCL program. On April 7th, 2017, Jefferies reiterated a buy rating on the stock and kept their price target at $17.
Beendete Einschätzungen von klostergang zu Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
03.12.18
04.11.21
17.06.21